Natalizumab induced blood eosinophilia: A retrospective pharmacovigilance cohort study and review of the literature.
Immunotherapy
Multiple sclerosis
Natalizumab
Pulmonary eosinophilia
Side effects
Journal
Journal of neuroimmunology
ISSN: 1872-8421
Titre abrégé: J Neuroimmunol
Pays: Netherlands
ID NLM: 8109498
Informations de publication
Date de publication:
15 04 2021
15 04 2021
Historique:
received:
03
12
2020
revised:
22
01
2021
accepted:
27
01
2021
pubmed:
7
2
2021
medline:
26
5
2021
entrez:
6
2
2021
Statut:
ppublish
Résumé
To describe frequency of natalizumab related eosinophilia and clinical symptoms of eosinophilic disease in our monocentric cohort. Comparison of clinical characteristics of 115 natalizumab treated and 116 untreated RRMS patients and review of literature. 38% of natalizumab treated patients had eosinophilia, which occurred significantly more frequently compared to untreated MS patients (3%, p-value<0.001). In symptomatic patients, mean eosinophil counts were significantly higher than in asymptomatic patients and symptoms developed within one year. Eosinophilia is a side effect of natalizumab and mostly asymptomatic. However, few patients develop within one year after start of natalizumab an eosinophilic disease as severe side effect.
Identifiants
pubmed: 33548621
pii: S0165-5728(21)00032-1
doi: 10.1016/j.jneuroim.2021.577505
pii:
doi:
Substances chimiques
Immunologic Factors
0
Natalizumab
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
577505Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.